Nolc1-KO Mouse
一般名
Nolc1-KO
製品ID
S-KO-17035
背景情報
C57BL/6JCya
系統ID
KOCMP-70769-Nolc1-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Nolc1-KO Mouse（カタログ番号S-KO-17035）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Nolc1-KO
系統ID
KOCMP-70769-Nolc1-B6J-VB
遺伝子名
製品ID
S-KO-17035
遺伝子別名
P130, NOPP130, NOPP140
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 19
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000165017
NCBIトランスクリプトID
NM_001039352.2
ターゲット領域
Exon 2~5
有効領域の大きさ
~1383 bp
遺伝子研究の概要
Nolc1, also known as Nucleolar and coiled-body phosphoprotein 1, is a nucleolar protein. It is responsible for nucleolus construction and ribosomal RNA (rRNA) synthesis, and acts as a chaperone shuttling between the nucleolus and cytoplasm. Nolc1 participates in multiple cellular life activities such as ribosome biosynthesis, DNA replication, transcription regulation, RNA processing, cell cycle regulation, apoptosis, and cell regeneration [1].
In cancer research, Nolc1 knockdown suppresses prostate cancer progressions by reducing AKT phosphorylation and β-catenin accumulation, indicating its role in promoting prostate cancer progression [2]. The Pten-NOLC1 fusion gene promotes cancers involving MET and EGFR signalings, acting as a driver for human cancers [3]. In endometrial cancer, NOLC1 is highly expressed in paclitaxel-resistant cells, and the SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance by inducing O-dysglycosylation [4]. In epithelial ovarian cancer, circ-NOLC1, which is derived from Nolc1, promotes tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression [5]. In colorectal cancer, high expression of NOLC1 is an independent prognostic factor for survival, enhancing cell proliferation and migration [6]. In esophageal carcinoma, NOLC1 overexpression is associated with poor prognosis, and knockdown of NOLC1 inhibits the PI3K-AKT pathway to improve the prognosis [8]. However, in thyroid cancer, Nolc1 is identified as a tumor suppressor gene [7].
In conclusion, Nolc1 is crucial for various cellular functions, especially in ribosome-related processes. Through gene-knockdown or fusion-gene models in cancer research, its role in promoting or suppressing different cancers has been revealed. Understanding Nolc1 provides new perspectives for cancer diagnosis and therapeutic target selection.
References:
1. Zhai, Fengguang, Wang, Jie, Luo, Xia, Ye, Meng, Jin, Xiaofeng. 2023. Roles of NOLC1 in cancers and viral infection. In Journal of cancer research and clinical oncology, 149, 10593-10608. doi:10.1007/s00432-023-04934-5. https://pubmed.ncbi.nlm.nih.gov/37296317/
2. Kim, Wansoo, Yeo, Dong-Yeop, Choi, Seong-Kyoon, Park, Jin-Kyu, Park, Song. 2022. NOLC1 knockdown suppresses prostate cancer progressions by reducing AKT phosphorylation and β-catenin accumulation. In Biochemical and biophysical research communications, 635, 99-107. doi:10.1016/j.bbrc.2022.10.038. https://pubmed.ncbi.nlm.nih.gov/36265288/
3. Luo, Jian-Hua, Liu, Silvia, Tao, Junyan, Tseng, George, Yu, Yan-Ping. 2020. Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. In Oncogene, 40, 1064-1076. doi:10.1038/s41388-020-01582-8. https://pubmed.ncbi.nlm.nih.gov/33323972/
4. Zhai, Fengguang, Li, Yuxuan, Zheng, Jingfei, Ye, Meng, Jin, Xiaofeng. 2025. SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation. In Oncogene, , . doi:10.1038/s41388-025-03347-7. https://pubmed.ncbi.nlm.nih.gov/40097806/
5. Chen, Shuo, Wu, Wu, Li, Qian-Hui, Wei, Xiao-Qing, Zhao, Yang. 2021. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. In Cell death discovery, 7, 22. doi:10.1038/s41420-020-00381-0. https://pubmed.ncbi.nlm.nih.gov/33483472/
6. Sun, Zhiwei, Zhang, Qianshi, Lv, Jinjuan, Zuo, Yun-Fei, Ren, Shuang-Yi. 2023. High expression of NOLC1 as an independent prognostic factor for survival in patients with colorectal cancer. In Journal of cancer research and clinical oncology, 149, 15697-15712. doi:10.1007/s00432-023-05297-7. https://pubmed.ncbi.nlm.nih.gov/37670166/
7. Zhai, Fengguang, Li, Yuxuan, Luo, Xia, Jin, Xiaofeng, Ye, Meng. 2024. NOLC1 was identified as a tumor suppressor gene in thyroid cancer and correlated with prognosis by bioinformatics. In American journal of cancer research, 14, 2055-2071. doi:10.62347/IYVV7581. https://pubmed.ncbi.nlm.nih.gov/38859850/
8. Kong, Fanguo, Shang, Yansheng, Diao, Xingyuan, Huang, Jiaguo, Liu, Hui. 2021. Knockdown of NOLC1 Inhibits PI3K-AKT Pathway to Improve the Poor Prognosis of Esophageal Carcinoma. In Journal of oncology, 2021, 9944132. doi:10.1155/2021/9944132. https://pubmed.ncbi.nlm.nih.gov/34046062/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。